These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20006922)

  • 81. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.
    Zhao T; Wang X; Xu T; Xu X; Liu Z
    Oncotarget; 2017 Aug; 8(31):51492-51506. PubMed ID: 28881662
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
    Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC
    Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease--a possible side effect?
    Georgalas I; Papaconstantinou D; Papadopoulos K; Pagoulatos D; Karagiannis D; Koutsandrea C
    Curr Drug Saf; 2014; 9(2):156-8. PubMed ID: 24517109
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Kidney injury during VEGF inhibitor therapy.
    den Deurwaarder ES; Desar IM; Steenbergen EJ; Mulders PF; Wetzels JF; van Herpen CM
    Neth J Med; 2012 Aug; 70(6):267-71. PubMed ID: 22859418
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
    Pandey AK; Singhi EK; Arroyo JP; Ikizler TA; Gould ER; Brown J; Beckman JA; Harrison DG; Moslehi J
    Hypertension; 2018 Feb; 71(2):e1-e8. PubMed ID: 29279311
    [No Abstract]   [Full Text] [Related]  

  • 86. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
    Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
    Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
    Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
    BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Renal Toxicities of Targeted Therapies.
    Abbas A; Mirza MM; Ganti AK; Tendulkar K
    Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
    Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
    Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
    [No Abstract]   [Full Text] [Related]  

  • 91. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
    Shye M; Hanna RM; Patel SS; Tram-Tran N; Hou J; Mccannel C; Khalid M; Hanna M; Abdelnour L; Kurtz I
    Clin Kidney J; 2020 Dec; 13(6):969-980. PubMed ID: 33391740
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients.
    Semeniuk-Wojtaś A; Lubas A; Stec R; Szczylik C; Niemczyk S
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941701
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
    Sorich MJ; Rowland A; Kichenadasse G; Woodman RJ; Mangoni AA
    Br J Cancer; 2016 Jun; 114(12):1313-7. PubMed ID: 27228299
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Bevacizumab-associated glomerular microangiopathy.
    Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
    Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Management of VEGF-Targeted Therapy-Induced Hypertension.
    Caletti S; Paini A; Coschignano MA; De Ciuceis C; Nardin M; Zulli R; Muiesan ML; Salvetti M; Rizzoni D
    Curr Hypertens Rep; 2018 Jun; 20(8):68. PubMed ID: 29959593
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
    Yeh J; Frieze D; Martins R; Carr L
    Ann Pharmacother; 2010 Jun; 44(6):1010-5. PubMed ID: 20460557
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists.
    Thangarasa T; Gotfrit J; Goodwin RA; Tang PA; Clemons M; Imbulgoda A; Vickers MM
    Curr Oncol; 2019 Apr; 26(2):e162-e166. PubMed ID: 31043822
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.
    Li M; Kroetz DL
    Pharmacol Ther; 2018 Feb; 182():152-160. PubMed ID: 28882537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.